Lv2
178 积分 2024-03-04 加入
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
2天前
已完结
Targeted Therapy for Primary Sjögren’s Syndrome: Where are We Now?
19天前
已完结
Sjögren’s syndrome
2个月前
已完结
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
2个月前
已完结
Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features
2个月前
已完结
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure
2个月前
已完结
Update on the pathophysiology and treatment of primary Sjögren syndrome
4个月前
已完结
AB0904 BELIMUMAB FOR THE TREATMENT OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS: A PHASE 2/3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
4个月前
已完结
The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus
4个月前
已完结
Autoimmune nodopathies, an emerging diagnostic category
5个月前
已完结
皖公网安备34019202002308
